Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.00 – $1.09
Volume15,955
Market cap$105M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for CLLS.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for CLLS.
Recent news
Company coverage with links to the original publishers.
Cellectis S.A. announced on September 14, 2026, that it would discontinue CAR-T cell therapy development (lasme-cel and eti-cel) to prioritize in vivo gene editing therapies, citing limited cash resources. The announcement triggered a 40.97% stock price decline, prompting a securities fraud investigation by Glancy Prongay Wolke & Rotter LLP on behalf of affected shareholders.
The Law Offices of Frank R. Cruz is investigating Cellectis S.A. for potential securities law violations following the company's September 14, 2026 announcement to discontinue CAR-T cell therapies (lasme-cel and eti-cel) and prioritize in vivo gene editing therapies due to limited cash resources. The announcement triggered a 40.97% stock price decline, causing investor losses.
Law firm Holzer & Holzer, LLC announced an investigation into whether Cellectis S.A. complied with federal securities laws following the company's September 14, 2026 announcement to exit development of lasme-cel and eti-cel. The announcement triggered a stock price decline, prompting the firm to seek investors who suffered losses to discuss potential legal action.
The CAR-T cell therapy market for acute lymphoblastic leukemia (ALL) is projected to grow at a 6.8% CAGR from 2026 to 2036, reaching from $300 million in 2025. The market is driven by approved therapies like KYMRIAH, TECARTUS, and AUCATZYL, with emerging innovations including allogeneic platforms and CD7-targeting therapies. Key challenges include relapse rates, manufacturing complexity, and toxicity management, while opportunities exist in earlier treatment lines and off-the-shelf platforms.
Cellectis, a clinical-stage biotechnology company specializing in gene editing and CAR T cell therapies, announced it will host a conference call and webcast on September 14, 2026 to provide a business update. The company will offer both English and French-language sessions with details on dial-in numbers and webcast links provided.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.